[Hybridomas in cancer].

Area of Science:

• Immunotechnology
• Biotechnology
• Cell Biology

Background:

• Monoclonal antibodies (mAbs) are crucial reagents in research and therapeutics.
• Hybridoma technology remains a cornerstone for producing specific mAbs.

Purpose of the Study:

• To review the established techniques for generating hybridomas.
• To provide an overview of experimental and clinical applications of hybridoma-derived mAbs.

Main Methods:

• Review of hybridoma production methodologies.
• Compilation of data from published experimental studies.
• Analysis of clinical trial outcomes involving mAbs.

Main Results:

• Successful generation of hybridomas is dependent on specific fusion and selection protocols.
• Hybridoma-derived mAbs have demonstrated efficacy in diverse research applications.
• Clinical trials show promising therapeutic potential across various diseases.

Conclusions:

• Hybridoma technology is a robust method for producing high-affinity, specific monoclonal antibodies.
• The application of these antibodies spans diagnostics, research, and targeted therapies.